Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Marco Dolci Biography and Net Worth

SVP of LivaNova

Marco Dolci joined LivaNova in 2017, coming from Danaher Corporation where he served as Vice President Danaher Business System-Dental Consumable Platform, earlier he was President Global Digital Dentistry and President Kerr EMEA and ASIA. Prior to his tenure at Danaher, Dolci served as President and CEO, EMEA for Hitachi Medical System Europe Holding AG. Earlier in his career, he worked in various positions at Eastman Kodak S.A. – Health Care Division, GE Healthcare and Philips Medical Systems. Dolci has more than 20 years of experience working in the healthcare and medical device industries.

Dolci earned a master’s degree in nuclear physics from University of Milan and an Executive MBA from Polytechnic University of Milan.

How do I contact Marco Dolci?: The corporate mailing address for Mr. Dolci and other LivaNova executives is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. LivaNova can also be reached via phone at 442033250660 and via email at [email protected]. Learn More on Marco Dolci's contact information.
Has Marco Dolci been buying or selling shares of LivaNova?: Marco Dolci has not been actively trading shares of LivaNova over the course of the past ninety days. Most recently, Marco Dolci sold 8,278 shares of the business's stock in a transaction on Tuesday, May 18th. The shares were sold at an average price of $82.91, for a transaction totalling $686,328.98. Learn More on Marco Dolci's trading history.
Who are LivaNova's active insiders?: LivaNova's insider roster includes Marco Dolci (SVP), Damien McDonald (CEO), Daniel Moore (Director), and Alfred Novak (Director). Learn More on LivaNova's active insiders.
Are insiders buying or selling shares of LivaNova?: During the last year, insiders at the sold shares 1 times. They sold a total of 56,623 shares worth more than $3,403,608.53. The most recent insider tranaction occured on June, 3rd when Director Daniel Jeffrey Moore sold 56,623 shares worth more than $3,403,608.53. Insiders at LivaNova own 0.3% of the company. Learn More about insider trades at LivaNova.
Information on this page was last updated on 6/3/2024.

Marco Dolci Insider Trading History at LivaNova

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/18/2021	Sell	8,278	$82.91	$686,328.98

Marco Dolci Buying and Selling Activity at LivaNova

LivaNova Company Overview

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $49.74

$49.74

$50.48

50 Day Range

MA: $52.01

$48.53

$53.83

2 Week Range

Now: $49.74

$42.75

$64.47

Volume

13,362 shs

Average Volume

612,943 shs

Market Capitalization

$2.70 billion

P/E Ratio

118.43

Dividend Yield

N/A

Beta

1.01